News

BREAKING NEWS – the radiopharmaceutical Gallium-68 (DOTA0-hel-Tyr3) octreotide (Ga-68 DOTATOC) has been designated as an orphan drug by the US Food and Drug Administration (FDA) for the management of neuroendocrine tumors. This designation is significant because it may lead to faster approval of the agent, which would greatly benefit carcinoid/NET patients in the United States. Click here to read the full release the Society of Nuclear Medicine and Molecular Imaging and from Josh Mailman, chairman of the Society’s Patient Advocacy Advisory Board and president of the NorCal CarciNET.

Photos from Warmth Manila

 Click here to view on non flash device.

Click on the photo to see full screen and to download.

A committee of international experts under the auspices of the International Atomic Energy Agency (IAEA), in cooperation with the EANM Therapy, Oncology and Dosimetry Committees and with the Society of Nuclear Medicine and Molecular Imaging, worked together to create this guidance document on the use of somatostatin analogue-based PRRNT. This 120 page guidance document released in February 2013, was compiled taking into account recent literature and experts’ opinion and can be downloaded here

AjitOur very dear friend and colleague, Prof. Dr. Ajit Kumar Padhy, passed away suddenly on the 22nd of August 2013 after suffering from a massive heart attack.

Prof Padhy was a Senior Consultant in the Singapore General Hospital, Department of Nuclear Medicine & PET since September 2005. Prior to that, he was the Head of Nuclear Medicine, IAEA, in the Division of Human Health from 1997 to 2004, and he was Faculty of Nuclear Medicine, AIIMS, New Delhi, India since the 1970’s.

For the third year, the Society of Nuclear Medicine and Molecular Imaging's Patient Advocacy Advisory Board developed a Patient Program to address key topics of interest to the patient and patient advocacy community.  These presentations were given at the SNMMI Patient Education Day, June 9th in Vancouver, BC.

Subcategories